160 related articles for article (PubMed ID: 11120956)
1. Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents.
Lee K; Chu CK
Antimicrob Agents Chemother; 2001 Jan; 45(1):138-44. PubMed ID: 11120956
[TBL] [Abstract][Full Text] [Related]
2. Understanding the mode of action of L-nucleosides as antiviral agents: a molecular modeling approach.
Lee K; Chong Y; Chu CK
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):385-8. PubMed ID: 11563052
[TBL] [Abstract][Full Text] [Related]
3. The role of 2',3'-unsaturation on the antiviral activity of anti-HIV nucleosides against 3TC-resistant mutant (M184V).
Choo H; Chong Y; Chu CK
Bioorg Med Chem Lett; 2003 Jun; 13(12):1993-6. PubMed ID: 12781181
[TBL] [Abstract][Full Text] [Related]
4. l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
Chong Y; Gumina G; Mathew JS; Schinazi RF; Chu CK
J Med Chem; 2003 Jul; 46(15):3245-56. PubMed ID: 12852755
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV.
Chong Y; Chu CK
Antiviral Res; 2004 Jul; 63(1):7-13. PubMed ID: 15196815
[TBL] [Abstract][Full Text] [Related]
6. Elucidating molecular interactions of
Hung M; Tokarsky EJ; Lagpacan L; Zhang L; Suo Z; Lansdon EB
Commun Biol; 2019; 2():469. PubMed ID: 31872074
[TBL] [Abstract][Full Text] [Related]
7. D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistance.
Wang J; Jin Y; Rapp KL; Schinazi RF; Chu CK
J Med Chem; 2007 Apr; 50(8):1828-39. PubMed ID: 17373782
[TBL] [Abstract][Full Text] [Related]
8. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
9. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
Menéndez-Arias L
Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
12. Understanding the molecular mechanism of drug resistance of anti-HIV nucleosides by molecular modeling.
Chong Y; Chu CK
Front Biosci; 2004 Jan; 9():164-86. PubMed ID: 14766357
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, and in vitro assay of novel nucleoside analog inhibitors against HIV-1 reverse transcriptase.
Liu X; Xie W; Huang RH
Bioorg Med Chem Lett; 2005 Aug; 15(16):3775-7. PubMed ID: 15993595
[TBL] [Abstract][Full Text] [Related]
15. 2'-Fluoro-4'-thio-2',3'-unsaturated nucleosides: anti-HIV activity, resistance profile, and molecular modeling studies.
Chong Y; Choo H; Schinazi RF; Chu CK
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):611-5. PubMed ID: 14565238
[TBL] [Abstract][Full Text] [Related]
16. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
17. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside reverse transcriptase inhibitors and HIV mutagenesis.
Jewell NA; Chen R; Raices R; Mansky LM
J Antimicrob Chemother; 2003 Oct; 52(4):547-50. PubMed ID: 12951341
[No Abstract] [Full Text] [Related]
20. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
